Biopharma group declares win against Janssen
An Irish biopharma company says it has received a final award in its dispute with Janssen Pharmaceuticals over the licensing of nanotechnology for the treatment of schizophrenia and HIV, which will enable it to obtain US$425 million in additional revenue.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.